FHTX

Foghorn Therapeutics Inc.

FHTX · CIK 1822462 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$23M
20202024
Net Income−$87M
20202024
Operating CF−$100M
20202024
Free Cash Flow−$101M
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.1B
SG&A Expense—————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-1.58$-2.34$-2.62$-2.73—
EPS (Diluted)$-1.58$-2.34$-2.62$-2.73—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.3B$0.3B$0.4B$0.5B$0.3B
Current Assets$0.2B$0.2B$0.4B$0.5B$0.2B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.1B
Total Liabilities$0.3B$0.4B$0.4B$0.4B$0.1B
Current Liabilities$0.1B$0.1B$0.1B$0.0B$0.0B
Stockholders' Equity$-0.0B$-0.1B$0.0B$0.1B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$0.2B$-0.1B$-0.0B
Investing Cash Flow$-0.0B$0.1B$-0.2B$0.0B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.0B$0.0B$0.2B
← Companies